A Systematic Review and Global Meta-analysis of Secondary Fungal Infections Associated with COVID-19

Aravind Murugavel,Sridevi Raghunathan,Jayapradha Ramakrishnan

DOI: https://doi.org/10.1101/2024.10.25.24316125

2024-10-27

Abstract:Summary Background: The COVID-19 pandemic has exposed patients to severe secondary fungal infections, exacerbating clinical outcomes and devastating impact. This study conducts a systematic review with meta-analysis of secondary fungal infections (SFIs) associated with COVID-19 considering various significant parameters, such as the frequency of SFIs across the globe, species shift, gender-specific infection rates, the significance of medical history, efficacy of steroid and antifungal, treatment outcomes (mortality rate), and fungal-polymicrobial mortality analysis. Methods: A literature search was conducted on COVID-19-related fungal infection studies (2020-2024) from SCOPUS and PUBMED databases, excluding preprints. The systematic data extraction captured the PMCID, country, patient demographics (age and gender), clinical outcomes, associated pathogens, medical history, and treatment details. Findings: The global meta-analysis of COVID-19-associated SFIs yielded 10,700 cases across 58 countries, exhibiting a significant male predominance (65.6% vs. 34.3% female). Aspergillus spp., Candida spp., and Mucorales spp. emerged as the primary fungal pathogens. The predominant six countries marking 80 % of global cases include India (46.8 %), Italy (10 %), Iran (9.4 %), France (5.1 %), Spain (4.3 %), and Egypt (4.1 %). Complication rates revealed CAM as the most prevalent (59.2%), with a 28% mortality rate. CAC (21.6%) and CAPA (19.1%) had substantially higher mortality rates, at 54% and 58%, respectively. Specific populations were highly affected, including individuals with diabetes were prone to CAM, those undergone catheterization were at increased risk of CAC, and individuals with respiratory diseases or without prior medical history were susceptible to CAPA. In both CAC and CAPA, the species shift towards the non-albicans spp. and non-fumigatus spp., associated with higher mortality. In addition, polymicrobial infection with fungal pathogens (Aspergillus spp., Candida spp., Mucorales spp.) and Multi-bacteria ( K. pneumoniae, P. aeruginosa, E. coli, S. aureus) also increased the mortality rate. Effective treatments were identified, including combining caspofungin with corticosteroids for CAC, voriconazole with dexamethasone for CAPA, and AmBisome monotherapy for CAM. Interpretation: In SFIs populations, CAM prevailed in high-density areas with relatively lower mortality rates, whereas CAC and CAPA exhibited higher mortality rates. Notably, polymicrobial infections significantly increased mortality across all SFIs. Underlying medical conditions primarily influenced the type of fungal pathogen, but treatment outcomes varied. Azole drugs and Amphotericin-B were ineffective against Candidiasis, except for caspofungin's limited susceptibility. Voriconazole and AmBisome demonstrated efficacy against Aspergillosis and Mucormycosis, respectively. Additionally, steroid administration proved life-saving in CAPA and CAC cases, yet remained ineffective in CAM.

Infectious Diseases (except HIV/AIDS)

What problem does this paper attempt to address?

The problems that this paper attempts to solve are as follows:

During the COVID - 19 pandemic, patients faced severe secondary fungal infections (SFIs), which aggravated the deterioration of clinical outcomes and the impact on patients. Through systematic review and global meta - analysis, this paper explores several important parameters related to secondary fungal infections associated with COVID - 19, including:

1. **Frequency of SFIs worldwide**: Research on the incidence of SFIs in different countries and regions.
2. **Species variation**: Analyze the changing trends of major pathogenic fungal species.
3. **Gender - specific infection rates**: Explore the differences in SFIs between male and female patients.
4. **Importance of medical history**: Evaluate the impact of patients' past medical history on the occurrence of SFIs.
5. **Efficacy of hormones and antifungal drugs**: Evaluate the effectiveness of hormones and antifungal drugs in the treatment of SFIs.
6. **Treatment outcomes (mortality)**: Analyze the impact of different treatment regimens on mortality.
7. **Mortality analysis of fungal - polymicrobial infections**: Explore the impact of co - infection of fungi and other microorganisms on mortality.

Specifically, through systematic review and meta - analysis, the paper aims to comprehensively understand the global distribution of SFIs, species variation, gender differences, the impact of medical history, treatment effects, and the impact of polymicrobial infections on mortality, so as to provide a scientific basis for clinical management and prevention strategies.